Genmab A/S (OTCMKTS:GNMSF) is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States. Over its history, the company has established multiple collaborations and licensing agreements with leading pharmaceutical partners—among them Janssen Pharmaceuticals, Novartis, BioNTech and Gilead Sciences—to advance its pipeline and bring products to market. These partnerships have yielded approved therapies and provided Genmab with access to extensive clinical development, regulatory and commercial expertise.
Genmab’s most advanced products include DARZALEX® (daratumumab), an anti-CD38 antibody co-developed and marketed with Janssen that has become a standard of care in multiple myeloma, and Tepezza® (teprotumumab), an anti-IGF-1R antibody approved for thyroid eye disease in collaboration with Horizon Therapeutics. In addition to these approvals, the company is progressing a diversified pipeline of investigational candidates across various hematologic malignancies and solid tumors, including epcoritamab, a bispecific CD3xCD20 antibody in late-stage clinical trials.
Genmab is led by Chief Executive Officer Jan van de Winkel, Ph.D., who has served in the role since 2012 and has overseen the company’s transition from early-stage research to a fully integrated biopharmaceutical enterprise. With a presence in key markets worldwide and a leadership team experienced in antibody science, clinical development and commercialization, Genmab continues to advance its mission of creating innovative antibody therapies to address unmet medical needs.
